Published in Urology on December 04, 2006
Ablative therapies for renal tumors. Ther Adv Urol (2010) 0.77
A novel method for texture-mapping conoscopic surfaces for minimally invasive image-guided kidney surgery. Int J Comput Assist Radiol Surg (2016) 0.75
Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy. Eur Urol (2008) 4.75
Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. J Urol (2007) 2.42
The state of prostate MRI in 2013. Oncology (Williston Park) (2013) 2.33
Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. Gastrointest Endosc (2003) 2.32
Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. Prostate (2008) 2.16
Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75. Urology (2009) 2.09
Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate. J Urol (2010) 2.05
Use of 111in-capromab pendetide immunoscintigraphy to image localized prostate cancer foci within the prostate gland. J Urol (2009) 2.03
Promoter hypermethylation profile of kidney cancer. Clin Cancer Res (2004) 2.02
Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prev (2008) 1.99
Rationale for percutaneous biopsy and histologic characterisation of renal tumours. Eur Urol (2012) 1.95
Bilateral focal ablation of prostate tissue using low-energy direct current (LEDC): a preclinical canine study. BJU Int (2013) 1.89
Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. J Urol (2009) 1.85
Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years. BJU Int (2007) 1.71
Defining potency: a comparison of the International Index of Erectile Function short version and the Expanded Prostate Cancer Index Composite. Cancer (2008) 1.71
Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer (2010) 1.59
Factors predicting prostatic biopsy Gleason sum under grading. J Urol (2009) 1.59
Complications of laparoscopic and percutaneous renal cryoablation in a single tertiary referral center. Eur Urol (2010) 1.53
Focal therapy for prostate cancer is a reasonable treatment option in properly selected patients. Urology (2009) 1.49
Overcoming challenges in designing and implementing a phase II randomized controlled trial using a presurgical model to test a dietary intervention in prostate cancer. Clin Trials (2008) 1.48
Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol (2002) 1.48
Current status of minimally invasive ablative techniques in the treatment of small renal tumours. Eur Urol (2006) 1.47
Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk. J Urol (2010) 1.45
Predicting occult multifocality of renal cell carcinoma. Eur Urol (2010) 1.45
Predictors of biochemical failure in patients undergoing prostate whole-gland salvage cryotherapy: a novel risk stratification model. BJU Int (2013) 1.44
Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol. Invest Radiol (2006) 1.43
Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. BJU Int (2011) 1.37
Treatment of localised renal cell carcinoma. Eur Urol (2011) 1.29
Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer (2007) 1.27
Changes in Gleason score grading and their effect in predicting outcome after radical prostatectomy. Urology (2009) 1.18
Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: the predictive role of age and prostate-specific antigen. Urology (2008) 1.15
Complications after percutaneous radiofrequency ablation of renal tumors. Urology (2005) 1.10
Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer. Hum Gene Ther (2003) 1.08
Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer. BJU Int (2008) 1.07
Editorial comment to Manually controlled targeted prostate biopsy with real-time fusion imaging of multiparametric magnetic resonance imaging and transrectal ultrasound: an early experience. Int J Urol (2014) 1.07
Can the conventional sextant prostate biopsy accurately predict unilateral prostate cancer in low-risk, localized, prostate cancer? Urol Oncol (2009) 1.07
Acoustic radiation force impulse imaging of human prostates: initial in vivo demonstration. Ultrasound Med Biol (2011) 1.06
Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy. BJU Int (2009) 1.06
Acoustic radiation force impulse imaging of human prostates ex vivo. Ultrasound Med Biol (2010) 1.04
Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death. BJU Int (2010) 1.04
Characterizing stiffness of human prostates using acoustic radiation force. Ultrason Imaging (2010) 1.04
Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer (2011) 1.04
Update on cryotherapy for prostate cancer in 2006. Curr Opin Urol (2006) 1.03
Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy. Cancer (2009) 1.02
Predicting unilateral prostate cancer on routine diagnostic biopsy: sextant vs extended. BJU Int (2009) 1.01
Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades: Duke University experience. Cancer (2010) 0.98
Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience. Urology (2007) 0.98
Cigarette smoking is associated with advanced renal cell carcinoma. J Clin Oncol (2011) 0.98
Prostate cancer: the new landscape. Curr Opin Urol (2009) 0.97
Zoledronic acid in the management of metastatic bone disease. Ther Clin Risk Manag (2008) 0.97
Focal therapy for prostate cancer: possibilities and limitations. Eur Urol (2010) 0.97
Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes? Urology (2009) 0.97
Factors predicting early and late phase decline of sexual health-related quality of life following radical prostatectomy. J Sex Med (2011) 0.96
Supplement use among men with prostate cancer. Urology (2005) 0.95
Effect of freeze time during renal cryoablation: a swine model. J Endourol (2006) 0.95
Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center. J Urol (2011) 0.94
Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen. Urology (2004) 0.94
Role of multiparametric magnetic resonance imaging (MRI) in focal therapy for prostate cancer: a Delphi consensus project. BJU Int (2014) 0.93
Effect of low-fat diets on plasma levels of NF-κB-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer. Cancer Prev Res (Phila) (2011) 0.92
Clinical predictors of renal mass pathological features. BJU Int (2010) 0.92
Urinary bladder cancer: role of MR imaging. Radiographics (2012) 0.92
Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model. Cancer Res (2003) 0.91
Short-term cancer control after primary cryosurgical ablation for clinically localized prostate cancer using third-generation cryotechnology. Urology (2007) 0.91
A retrospective comparison of anesthetic management of robot-assisted laparoscopic radical prostatectomy versus radical retropubic prostatectomy. J Clin Anesth (2009) 0.91
Management of small renal tumors with radiofrequency ablation. Urology (2003) 0.91
The effect of noise-cancelling headphones or music on pain perception and anxiety in men undergoing transrectal prostate biopsy. Urology (2012) 0.91
Pathological T2 sub-divisions as a prognostic factor in the biochemical recurrence of prostate cancer. BJU Int (2010) 0.90
Tumor volume, tumor percentage involvement, or prostate volume: which is predictive of prostate-specific antigen recurrence? Urology (2009) 0.90
Impact of primary Gleason grade on risk stratification for Gleason score 7 prostate cancers. Int J Radiat Oncol Biol Phys (2011) 0.90
Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer (2002) 0.90
Autoimmune testicular vasculitis. Urology (2003) 0.88
The rise of ablative technologies for treating the small renal mass. Eur Urol (2007) 0.88
Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era. Anticancer Res (2014) 0.88
Outcomes of salvage prostate cryotherapy stratified by pre-treatment PSA: update from the COLD registry. World J Urol (2012) 0.87
Role of oxidative stress in a rat model of radiation-induced erectile dysfunction. J Sex Med (2012) 0.87
Radiation-induced erectile dysfunction using prostate-confined modern radiotherapy in a rat model. J Sex Med (2011) 0.87
Predictors of prolonged operative time during robot-assisted laparoscopic radical prostatectomy. BJU Int (2010) 0.87
Analysis of laterality and percentage of tumor involvement in 1386 prostatectomized specimens for selection of unilateral focal cryotherapy. Technol Cancer Res Treat (2007) 0.87